22:47 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Hypertriglyceridemia Rat studies suggest combined inhibition of MMP1 and MMP3 could help treat hypertriglyceridemia. In a rat model of diet-induced hypertriglyceridemia, subcutaneous administration of a previously reported dual MMP1/MMP3 inhibitor decreased liver weight, serum triacylglyceride,...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest a hydrogel-based formulation of the GCCR agonist triamcinolone acetonide could help treat RA and other forms of inflammatory arthritis. The hydrogel contains injectable triglycerol monostearate that...
08:00 , Dec 5, 2011 |  BioCentury  |  Product Development

Change-up for BATTER-UP

A year after starting a biomarker study in rheumatoid arthritis, a broad-based consortium has been forced to retool its recruitment strategy. The Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis -Unresponsive Populations Consortium had hoped...
07:00 , May 19, 2011 |  BC Innovations  |  Targets & Mechanisms

Dendrimer throws a blanket on RA

A research group in France has developed an azabisphosphonate-capped dendrimer that blocks inflammation, cartilage degradation and bone erosion in mouse models of rheumatoid arthritis.1 The group is getting the compound ready for clinical trials. Dendrimers are...
07:00 , Jun 3, 2010 |  BC Innovations  |  Cover Story

HIF2A: mastering osteoarthritis

Most approved osteoarthritis therapies treat symptoms of the disease but not the underlying processes that lead to cartilage destruction and bone spur formation in joints. Now, separate research teams from Japan and South Korea have...
07:00 , Sep 3, 2009 |  BC Innovations  |  Cover Story

SDC4: OA joint effort

Most approved osteoarthritis therapies are NSAIDs that treat the symptoms but do not halt the progress of the disease. Indeed, joint replacement surgery is the only curative strategy. Now, a team of German and South...
07:00 , Oct 25, 2004 |  BC Week In Review  |  Company News

Millennium other research news

MLNM's studies using an RA patient registry containing genetic and proteomic data from about 1,000 patients identified biomarkers indicative of treatment success with disease modifying anti-rheumatic drugs (DMARDs). Specifically, they found elevated serum proteins, MMP3...